Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study

Table 4

Summary of adverse events.

	Tenapanor 10 mg (n = 12)	Tenapanor 30 mg (n = 12)	Tenapanor 50 mg Chinese (n = 12)	Tenapanor 50 mg caucasian (n = 11)	Placebo (n = 12)
Participants experiencing at least 1 TEAE	5 (41.7%)	7 (58.3%)	12 (100%)	11 (100%)	6 (50.0%)
AEs occurring in at least 2 participants in any group
Diarrhea	2 (16.7%)	0	12 (100%)	11 (100%)	1 (8.3%)
Increased systolic blood pressure	1 (8.3%)	3 (25.0%)	0	1 (9.1%)	0
Hypertriglyceridemia	1 (8.3%)	2 (16.7%)	0	0	1 (8.3%)
Hyperlipidemia	1 (8.3%)	0	2 (16.7%)	0	0
Fever	0	0	3 (25.0%)		1 (8.3%)
Abdominal distention	0	0	0	3 (27.3%)	0
Increased transaminases	1 (8.3%)	2 (16.7%)	0	0	0
Arrhythmia	0	2 (16.7%)	0	0	0

AE adverse event, TEAEtreatment-emergent adverse event.